Ikarian Capital’s DiaMedica Therapeutics DMAC Stock Holding History

Ikarian Capital’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-221,252	Closed	-$553K	–	159
2022 Q1	$553K	Buy	221,252 +12,170	+6%	+$34.5K	0.07%	131
2021 Q4	$779K	Sell	209,082 -101,959	-33%	-$400K	0.12%	109
2021 Q3	$1.25M	Sell	311,041 -103,959	-25%	-$398K	0.09%	149
2021 Q2	$1.85M	Hold	415,000	–	–	0.15%	137
2021 Q1	$3.8M	Hold	415,000	–	–	0.13%	149
2020 Q4	$4.21M	Hold	415,000	–	–	0.19%	105
2020 Q3	$1.76M	Buy	+415,000	New	+$2.2M	0.13%	116

Other funds holding DMAC

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ikarian Capital's DMAC Position: Q2 2022 in Review

Ikarian Capital sold out of DiaMedica Therapeutics (DMAC) in Q2 2022, closing a stake of 221,252 shares — an estimated $553K sold.

Ikarian Capital first reported a position in DMAC in Q3 2020 and held it in 7 quarters. The position peaked at $4.21M in Q4 2020. 28 funds tracked by Wall St. Rank hold DMAC as of Q2 2022.

Ikarian Capital reported no remaining DiaMedica Therapeutics position as of Q2 2022 after selling out during the quarter.
Ikarian Capital sold 221,252 DiaMedica Therapeutics shares in Q2 2022, an estimated $553K.
Ikarian Capital first reported a position in DiaMedica Therapeutics in Q3 2020 and held it in 7 quarters.
Ikarian Capital's DiaMedica Therapeutics position peaked at $4.21M in Q4 2020.
28 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.